Optimizing Outcomes in Breast Reconstruction: The Role of Hormonal Therapy Management

Breast cancer comprises diverse subtypes with prognostic and therapeutic implications. Hormone therapy plays a crucial role in managing tumors expressing hormonal receptors, but its impact on breast reconstruction outcomes remains unclear. This study aims to evaluate the association between perioperative hormone therapy continuation and the incidence of postoperative complications following breast reconstruction (including autologous, prosthetic, and hybrid techniques), with a focus on identifying specific complication types to refine patient management strategies.

A retrospective analysis was conducted on patients who underwent breast reconstruction following mastectomy for hormone receptor-positive breast cancer. Patients were categorized based on the appropriate discontinuation of hormonal therapy. Clinical data, including patient characteristics, treatment regimens, and complication occurrences, were registered and analyzed.

Inadequate suspension of hormonal therapy during the perioperative period was significantly associated with a higher rate of complications, particularly in the immediate and early phases. Complications such as skin alterations, flap failure, seroma development, and clinical infection showed significant associations with the continuation of hormone therapy (p < 0.05). No significant differences were observed for other complications.

Preliminary findings suggest a potential correlation between the continuation of hormone therapy during the perioperative phase and the development of complications following breast reconstruction.